Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Transfusion ; 55(8): 2032-8, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25857853

RESUMEN

BACKGROUND: Although the mobilization of hematopoietic progenitor stem cells from healthy donors (HDs) using granulocyte-colony-stimulating factor is widely used, the ideal method for the administration of the cytokine has not yet been determined. STUDY DESIGN AND METHODS: Seventy-five consecutive HDs received lenograstim (LENO) as mobilization agent. LENO was given subcutaneously at a dose of 10 µg/kg in a once-daily dose (ODD) every 24 hours. Results were compared with a historical control group of 181 HDs treated with 5 µg/kg LENO twice-daily dose (TDD) with a time interval of 12 hours. RESULTS: CD34+ cell concentrations evaluated on Day 4 and on Day 5 were 45 × 10(6) (range, 6 × 10(6) -217 × 10(6) )/L and 75 × 10(6) (range, 7 × 10(6) -279 × 10(6) )/L with ODD versus 36 × 10(6) (range, 3 × 10(6) -200 × 10(6) )/L and 55 × 10(6) (range, 3 × 10(6) -738 × 10(6) )/L with TDD (p = 0.067 and p = 0.001). The collected CD34+ cell counts in first apheresis procedure were 5.6 × 10(6) ± 2.9 × 10(6) and 5.7 × 10(6) ± 3 × 10(6) /kg donor and recipient body weight in the ODD versus 5.4 × 10(6) ± 3.8 × 10(6) and 5.3 × 10(6) ± 3.5 × 10(6) /kg in the TDD cohort, respectively (p = 0.08 and p = 0.02). Five HDs (6.7%) mobilized CD34+ cells of fewer than 2 × 10(6) /kg recipient body weight in the ODD group compared with seven HDs (3.9%) in the TDD group (p = 0.3). CONCLUSIONS: Once-daily administration of LENO is at least as effective as twice-daily administration for the mobilization of CD34+ cells in HDs.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos/farmacología , Adulto , Aloinjertos , Antígenos CD34/sangre , Eliminación de Componentes Sanguíneos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Fatiga/inducido químicamente , Femenino , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Enfermedades Hematológicas/terapia , Movilización de Célula Madre Hematopoyética/métodos , Estudio Históricamente Controlado , Humanos , Inyecciones Subcutáneas , Lenograstim , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Neoplasias/terapia , Dolor/inducido químicamente , Estudios Prospectivos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/farmacología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA